Flagship named Company of the Year by CIOReview

November 13, 2018 – CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, […]

Read More

GEN Features Flagship Solutions, cTA Platform

November 8, 2018 – Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in Boston. Dr. Joseph Krueger, Flagship Chief Science Officer, presented Flagship’s approach at the conference. Flagship’s cTA platform can help […]

Read More

Flagship Presents AI Solutions at SITC

November 7, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven immunotherapy solutions at the SITC annual conference, November 9-10, 2018, in Washington DC. Flagship will present a poster, “Using Artificial Intelligence to Predict Response to Immunotherapy,” (P90) at the Washington Convention Center, Hall E, on Friday, Nov. 9 and Saturday, Nov. 10. […]

Read More

Flagship Presents at Pathology Visions 2018

November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA. Learn more and download the poster here: Pathology AI (Artificial Intelligence)

Read More

Flagship Recognized Among 10 Best Technology Solution Providers of 2018

October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking approach that integrates multiple technologies, including its proprietary cTA platform, with a multidisciplinary team to deliver […]

Read More

Predicine and Flagship Biosciences Partner to Support Global Biomarker Development

Predicine and Flagship Biosciences are excited to announce a strategic venture to provide complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space.

Read More

Flagship Receives Global Technology Innovation Award

Frost & Sullivan News Release: Flagship Biosciences Recognized by Frost & Sullivan for Its Industry-leading AI-powered cTA® Platform for Predictive Diagnostics Santa Clara, CA, September 18, 2018 – Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with […]

Read More

Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine

Westminster, CO, September 6, 2018 – Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of […]

Read More

Flagship Secures Series A Funding to Accelerate Growth in Drug Development and Diagnostics Services

Westminster, CO, July 10, 2018 – Flagship Biosciences has closed a series A round of funding to advance the growth of its computational tissue image analysis technology platform and biomarker-driven drug development and diagnostic services. Since 2009, Flagship’s integrated team of scientists, pathologists, tissue and data analysts, and software engineers has worked with some of […]

Read More

Flagship publishes article on using IHC and digital imaging to improve patient selection for PD-L1 therapy

First NSCLC study using cTA to report IHC data in immuno-oncology Westminster, CO, June 7, 2018 – Flagship is proud to co-author the research paper, PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters, published June 6, 2018, in PLOS ONE, an open access peer-reviewed journal. The paper is the first Non-Small […]

Read More